Vaccibody vaccines consist of three modules, each of them serving a crucial purpose to increase efficacy. They can easily be optimally designed for a given disease based on Vaccibody’s expertise within advanced immunology. The Technology Platform is versatile and the vaccines can be delivered as DNA, RNA or Protein.
The main feature of the Vaccibody Vaccine Technology Platform is the ability to attract and target Antigen Presenting Cells (APCs) which are known to be essential to initiate an effective immune response. Binding by the vaccine’s targeting module to receptors on APCs leads to rapid internalization of the Vaccibody vaccine and mediates maturation of the APC.
These events result in enhanced presentation of the internalized antigen to both Helper T cells and Cytotoxic T cells, both crucial to initiate a strong and effective immune response. Vaccibody vaccines can harbour whole, intact proteins as antigenic modules that can be recognized by B cells and stimulate antibody production with the help from Helper T cells.
The modular format of the Vaccibody vaccines facilitates an easy and fast modification of the structure to create individualized vaccines as well as off the shelf optimal Vaccines for each disease.
Therapeutic Vaccibody vaccines against cancer can be optimized for induction of Cytotoxic T cells that kill cancerous cells, see Cancer Vaccines.
Prophylactic Vaccibody vaccines against infectious diseases can be deliberately optimized for induction of protective antibody responses that neutralize the pathogen–see Infectious Diseases
Therapeutic or Prophylactic Vaccines
Compatible with individualized vaccine development
Target vaccines to Antigen Presenting Cells
Constitute potent and effective vaccines
Stimulate either or both B cell and T cell immunity
Administration as DNA, RNA or Protein